Get the Stockscreener App
2.615
1.69%
-0.045
Lipocine Inc stock is traded at $2.615, with a volume of 3,836.
It is down -1.69% in the last 24 hours and down -21.94% over the past month.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
See More
Previous Close:
$2.66
Open:
$2.66
24h Volume:
3,836
Relative Volume:
0.12
Market Cap:
$14.27M
Revenue:
-
Net Income/Loss:
$-16.35M
P/E Ratio:
-0.8574
EPS:
-3.05
Net Cash Flow:
$-11.88M
1W Performance:
-7.27%
1M Performance:
-21.94%
6M Performance:
-21.71%
1Y Performance:
-56.99%
1-Day Range:
$2.634
$2.71
1-Week Range:
$2.57
$2.83
52-Week Range:
$2.57
$6.1683
Lipocine Inc Stock (LPCN) Company Profile
Name
Lipocine Inc
Sector
Industry
Phone
801 994 7383
Address
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
2.634 | 14.41M | 0 | -16.35M | -11.88M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.63 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.39 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.26 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
821.78 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.80 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-12-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-11-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| Dec-08-17 | Resumed | H.C. Wainwright | Buy |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
| Jun-23-15 | Initiated | Canaccord Genuity | Buy |
View All
Lipocine Inc Stock (LPCN) Latest News
Lipocine Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
Will Lipocine Inc. stock outperform value stocksMarket Sentiment Report & High Accuracy Swing Entry Alerts - newser.com
How Lipocine Inc. stock performs after earningsJuly 2025 Price Swings & Expert Verified Movement Alerts - newser.com
Will Lipocine Inc. stock go up soon2025 Key Highlights & AI Enhanced Trading Signals - newser.com
How Lipocine Inc. stock reacts to inflationary pressuresPortfolio Return Summary & Capital Protection Trade Alerts - newser.com
Is Lipocine Inc. stock a safe buy before earningsJuly 2025 News Drivers & Free High Accuracy Swing Entry Alerts - newser.com
Is Lipocine Inc. stock trading near support levelsEarnings Risk Report & Consistent Return Strategy Ideas - newser.com
How to build a dashboard for Lipocine Inc. stockEarnings Overview Report & Free Technical Pattern Based Buy Signals - newser.com
Smart tools for monitoring Lipocine Inc.’s price action2025 Investor Takeaways & Growth Focused Stock Pick Reports - newser.com
Will a bounce in Lipocine Inc. offer an exitNew Guidance & Daily Price Action Insights - newser.com
Why analysts upgrade Lipocine Inc. stockWatch List & Safe Entry Point Identification - newser.com
Lipocine, Inc. Stock Plummets to New 52-Week Low of $2.57 - Markets Mojo
Is Lipocine Inc. stock attractive for long term wealth buildingWeekly Market Summary & Momentum Based Trading Ideas - newser.com
What margin trends mean for Lipocine Inc. stockJuly 2025 Trade Ideas & Capital Efficiency Focused Strategies - fcp.pa.gov.br
Is Lipocine Inc. stock dividend yield sustainableRecession Risk & Free Fast Entry Momentum Trade Alerts - Fundação Cultural do Pará
How risky is Lipocine Inc. stock now2025 Historical Comparison & Weekly Stock Performance Updates - fcp.pa.gov.br
Lipocine Inc Stock (LPCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):